Down 99%, this stock has been crushed by AI and is now a penny share!

Chegg has gone from being a fast-growth tech stock to a penny share trading for less than $1 in the space of four years. Ben McPoland explains why.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Frustrated young white male looking disconsolate while sat on his sofa holding a beer

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The market has recently moved on from all things artificial intelligence (AI), focusing instead on global trade and tariffs. But in the background, the AI revolution continues apace and is disrupting some businesses. One is Chegg (NYSE: CHGG), which was trading for $113 in 2021 but is now priced as a penny share at $0.75.

That’s a shocking four-year decline of 99%!

An example of disruption

Chegg is an education technology company that offers services like textbook rentals, homework help, and study resources. Its customers are mainly college and high school students. 

However, as we know, generative AI bots like ChatGPT now — somewhat controversially — offer free help with homework and essays, undermining Chegg’s value proposition. Basically, students seem to be thinking: ‘why pay for Chegg when AI gives you free answers?’

In 2023, management said: “Since March we saw a significant spike in student interest in ChatGPT. We now believe it’s having an impact on our new customer growth rate.”

Chegg was right. In two years, its subscribers have gone from 5.1m to 3.2m, with revenue falling from $188m to $121m in that time. Worryingly, its cash position has fallen from $281m in Q1 2023 to just $44m at the end of March (and it’s now loss-making).

To try to improve things, the company is drastically cutting costs and exploring being acquired. Perhaps that can salvage some value (the market cap is now just $79m).

It’s also licensing its question-and-answer pairs to language model companies, though that appears to be a double-edged sword to me. Yes, it’s generating revenue by leveraging proprietary education data, but giving AI companies its content could cannibalise the core subscription business.

Today (12 May), Chegg’s management wrote: “We believe the trends impacting our business will worsen before they get better.”

Those “trends” are, of course, mainly declining subscribers due to competition from generative AI.

AI is not a single event

Many people have likened AI to the internet, but it does appear different to me.

While revolutionary, the internet was a one-time platform shift. But AI is not a single watershed moment. Rather, it’s a self-improving force, constantly learning and evolving, perhaps exponentially. 

Consequently, I expect a lot more disruption — and potential opportunities — in the years ahead.

This stock looks in no danger from AI

Of course, there will be some businesses that AI won’t hurt. It should even make them more efficient and profitable. Many of these can be found in the FTSE 100, including miners, global banks, and oil giants.

One UK stock that might be worth considering is AstraZeneca. It’s down 16% since March as investors worry about the Trump administration’s drive to lower drug prices in the US. This is a risk worth mentioning, as the US is AstraZeneca’s largest market.

However, in terms of AI, the technology could actually turbocharge the company’s drug discovery process. Not only that, but AstraZeneca has the wherewithal to really invest in its AI capabilities, unlike most smaller upstarts.

To me, the firm looks more likely to benefit from AI than be threatened by it. With the stock trading at a reasonable 15 times forward earnings, I think it’s worth a look.

Ben McPoland has positions in AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Female student sitting at the steps and using laptop
Investing Articles

How much do you need in an ISA to target £8,333 a month of passive income?

Our writer explores a potential route to earning double what is today considered a comfortable retirement and all tax-free inside…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Could these 3 FTSE 100 shares soar in 2026?

Our writer identifies a trio of FTSE 100 shares he thinks might potentially have more petrol in the tank as…

Read more »

Pakistani multi generation family sitting around a table in a garden in Middlesbourgh, North East of England.
Dividend Shares

How much do you need in a FTSE 250 dividend portfolio to make £14.2k of annual income?

Jon Smith explains three main factors that go into building a strong FTSE 250 dividend portfolio to help income investors…

Read more »

Tesla building with tesla logo and two teslas in front
Investing Articles

275 times earnings! Am I the only person who thinks Tesla’s stock price is over-inflated?

Using conventional measures, James Beard reckons the Tesla stock price is expensive. Here, he considers why so many people appear…

Read more »

Investing Articles

Here’s what I think investors in Nvidia stock can look forward to in 2026

Nvidia stock has delivered solid returns for investors in 2025. But it could head even higher in 2026, driven by…

Read more »

Investing Articles

Here are my top US stocks to consider buying in 2026

The US remains the most popular market for investors looking for stocks to buy. In a crowded market, where does…

Read more »

Investing Articles

£20,000 in excess savings? Here’s how to try and turn that into a second income in 2026

Stephen Wright outlines an opportunity for investors with £20,000 in excess cash to target a £1,450 a year second income…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

Is a 9% yield from one of the UK’s most reliable dividend shares too good to be true?

Taylor Wimpey’s recent dividend record has been outstanding, but investors thinking of buying shares need to take a careful look…

Read more »